Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06085716 · ClinicalTrials.gov registry record · Phase 2
Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers
A Phase 2 study of Fatigue and Metastatic Cancers, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 240
- Enrollment target
- 1
- Study location
NCT06085716: Recruiting Phase 2 study of Fatigue and Metastatic Cancers, sponsored by M.D. Anderson Cancer Center.
NCT06085716 is a Phase 2 study of Fatigue and Metastatic Cancers that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 240 participants, above the 216-participant average among 109 other Fatigue trials with a reported enrollment target (11% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06085716, a Phase 2 study of Fatigue and Metastatic Cancers, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 240 participants
- Enrollment target
- 1
- Study location
Study Summary
To find out if combining psychoeducational interventions (such as education, counseling, and self-managed therapies) with an open-label placebo can help to improve your quality of life better than either the psychoeducational interventions or the placebo alone.
Conditions Studied
Interventions
- BEHAVIORAL Psychoeducational Intervention
- DRUG Open Label Placebo
- BEHAVIORAL Psychoeducational Intervention+Placebo
Study Locations (1)
Texas
- MD Anderson Cancer Centerr - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 240 participants |
| Start Date | 2024-02-16 |
| Est. Completion | 2029-08-31 |
| Phase | Phase 2 |
What NCT06085716 shows while recruiting
NCT06085716 is an interventional study that assigns participants to a tested intervention. The registered 240 participants enrollment target is mid-sized for trials with a published cap, above the 216-participant average among 109 other Fatigue trials with a reported enrollment target (11% higher).
The record links to 2 conditions, with Fatigue appearing as the primary indexed condition, and to 3 interventions - of which Psychoeducational Intervention is the first listed.
NCT06085716 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06085716 about?
NCT06085716 is a clinical study titled "Combination Therapy for Cancer Related Fatigue in Patients With Metastatic Cancers". To find out if combining psychoeducational interventions (such as education, counseling, and self-managed therapies) with an open-label placebo can help to improve your quality of life better than either the psychoeducational interventions or the placebo alone.
What is the current status of trial NCT06085716?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 240 participants. The study started on 2024-02-16. Estimated completion is 2029-08-31.
What conditions does trial NCT06085716 study?
This clinical trial studies the following conditions: Fatigue, Metastatic Cancers.
What interventions are being tested in trial NCT06085716?
The interventions under investigation include: Psychoeducational Intervention (BEHAVIORAL), Open Label Placebo (DRUG), Psychoeducational Intervention+Placebo (BEHAVIORAL).
Who is sponsoring clinical trial NCT06085716?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06085716 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Fatigue
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06085716's enrollment target sits among peer trials
240 17th of 109 higher than 93 of 109 other Fatigue trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Fatigue trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Improving Cancer-related Fatigue, Sexual Dysfunction and Quality of Life in Older Men With Cancer and Androgen Deficiency
RECRUITING · Phase 2
-
Take the Reins: The Effects of Nutrient Timing on Cancer-related Fatigue
RECRUITING · Phase 2
-
Clinical Trial of the Seaweed Supplement Fucoidan in Survivors of Cancer
RECRUITING · Phase 2
-
Transcranial Direct Current Stimulation for Post-stroke Fatigue
RECRUITING · Phase 2
-
Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02855554 · 240 participants · NA
Quantitative Cardiac Parametric Mapping
- NCT03230565 · 240 participants · Phase 4
Continuous Infusions vs Scheduled Bolus Infusions
- NCT03399929 · 240 participants
Traumatic Brain Injury and Stroke Long Term Outcome
- NCT03583710 · 240 participants · Phase 3
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI